內地醫藥生物板塊急升 君實及信達生物漲逾半成
滬指及深成午後升幅擴至1.3%及1.8%,報3,091及11,163。醫藥生物板塊午後抽升4.7%,有近20隻個股漲10%-20%。
本港相關股以君實生物(01877.HK)及信達生物(01801.HK)彈力最強,股價反覆回升逾半成,最高見25元及25.45元,現報24.85元及25.2元,回升逾5%。開拓藥業-B(09939.HK)曾反覆彈6.5%午後高見11.4元,現報11.12元,回升3.9%。
康希諾生物1(06185.HK)反覆回升3.6%報45.15元,康希諾A(688185.SH)升4%報117.88元人民幣。此外,藥明康德(02359.HK)及藍籌藥明生物(02269.HK)反覆續彈逾2%,報65.55元及49.1元。藍籌石藥(01093.HK)反覆續彈升2.5%報7.32元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.